NEW YORK (GenomeWeb News) — GeneGo today said that Galapagos will use its MetaCore software for internal research across “several disease areas” including osteoporosis, osteoarthritis, and rheumatoid arthritis.
 
Galapagos has previously used its adenoviral technology to identify and validate targets in bone and joint diseases, and applying MetaCore to these targets “could allow us to gain valuable insights at the system level,” Galapagos said in a statement.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.